Peter Esser1, Katharina Kuba1, Anja Mehnert1, Christoffer Johansen1,2,3, Andreas Hinz1, Florian Lordick4, Heide Götze1. 1. Department of Medical Psychology and Medical Sociology, University Medical Center Leipzig, Leipzig, Germany. 2. Oncology Clinic, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 3. Unit of Survivorship, The Danish Cancer Society Research Center, Copenhagen, Denmark. 4. University Cancer Center Leipzig (UCCL), University Medical Center Leipzig, Leipzig, Germany.
Abstract
OBJECTIVES: Quality of life (QoL) has become an important tool to guide decision making in oncology. Given the heterogeneity among hematological cancer survivors, however, clinicians need comparative data across different subsets. METHODS: This study recruited survivors of hematological malignancies (≥2.5 years after diagnosis) from 2 German cancer registries. QoL was assessed with the EORTC QLQ-C30. The sample was stratified by cancer type, time since diagnosis, treatment with stem cell transplantation (SCT) and type of SCT. First, levels of QoL were compared across subsamples when controlling for several covariates. Second, we contrasted subsamples with gender- and age-matched population controls obtained from the general population. RESULTS: Of 2001 survivors contacted by mail, 922 (46%) participated in the study. QoL did not significantly differ between the subsamples. All subsamples scored significantly lower in functioning and significantly higher in symptom burden compared to population controls (all P < .001). Almost all of these group effects reached clinically meaningful sizes (Cohen's d ≥ .5). Group differences in global health/QoL were mostly non-significant. CONCLUSIONS: Hematological cancer survivors are associated with practically relevant impairments irrespective of differences in central medical characteristics. Nevertheless, survivors seem to evaluate their overall situation as relatively well.
OBJECTIVES: Quality of life (QoL) has become an important tool to guide decision making in oncology. Given the heterogeneity among hematological cancer survivors, however, clinicians need comparative data across different subsets. METHODS: This study recruited survivors of hematological malignancies (≥2.5 years after diagnosis) from 2 German cancer registries. QoL was assessed with the EORTC QLQ-C30. The sample was stratified by cancer type, time since diagnosis, treatment with stem cell transplantation (SCT) and type of SCT. First, levels of QoL were compared across subsamples when controlling for several covariates. Second, we contrasted subsamples with gender- and age-matched population controls obtained from the general population. RESULTS: Of 2001 survivors contacted by mail, 922 (46%) participated in the study. QoL did not significantly differ between the subsamples. All subsamples scored significantly lower in functioning and significantly higher in symptom burden compared to population controls (all P < .001). Almost all of these group effects reached clinically meaningful sizes (Cohen's d ≥ .5). Group differences in global health/QoL were mostly non-significant. CONCLUSIONS:Hematological cancer survivors are associated with practically relevant impairments irrespective of differences in central medical characteristics. Nevertheless, survivors seem to evaluate their overall situation as relatively well.
Authors: Christopher S Strouse; Melissa C Larson; Shawna L Ehlers; Kathleen J Yost; Matthew J Maurer; Stephen M Ansell; David J Inwards; Patrick B Johnston; Ivana N Micallef; Brian K Link; Umar Farooq; James R Cerhan; Carrie A Thompson Journal: JCO Oncol Pract Date: 2022-05-20
Authors: Giorgio La Nasa; Giovanni Caocci; Emanuela Morelli; Elena Massa; Antonio Farci; Laura Deiana; Elisa Pintus; Mario Scartozzi; Federica Sancassiani Journal: Clin Pract Epidemiol Ment Health Date: 2020-07-30
Authors: Katharina Kuba; Gregor Weißflog; Heide Götze; Francisco García-Torres; Anja Mehnert; Peter Esser Journal: Int J Clin Health Psychol Date: 2019-01-16
Authors: Pushpendra Goswami; Esther N Oliva; Tatyana Ionova; Roger Else; Jonathan Kell; Adele K Fielding; Daniel M Jennings; Marina Karakantza; Saad Al-Ismail; Graham P Collins; Stewart McConnell; Catherine Langton; Magda J Al-Obaidi; Metod Oblak; Sam Salek Journal: Front Pharmacol Date: 2020-09-08 Impact factor: 5.810
Authors: Victoria M White; Karolina Lisy; Andrew Ward; Eli Ristevski; Melanie Clode; Kate Webber; Jon Emery; Maarten J Ijzerman; Nina Afshar; Jeremy Millar; Peter Gibbs; Sue Evans; Michael Jefford Journal: Support Care Cancer Date: 2022-03-12 Impact factor: 3.359